Patents by Inventor Anke Klippel-Giese

Anke Klippel-Giese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11649227
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: May 16, 2023
    Assignee: Petra Pharma Corporation
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Markus K. Dahlgren, Shulu Feng, Aleksey I. Gerasyuto, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Anke Klippel-Giese, Jennifer Lynn Knight, Gabrielle R. Kolakowski, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, David L. McElligott, Johnathan Alexander McLean, Loredana Puca, Kannan Karukurichi Ravi, Daniel Lee Severance, Michael Brian Welch, Tien Widjaja
  • Patent number: 11578328
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: February 14, 2023
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10774332
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 15, 2020
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10329568
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10323246
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 18, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10266829
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 23, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20180291381
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 11, 2018
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9790501
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 17, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9790505
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 17, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9783802
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 10, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9758784
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: September 12, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9695423
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 4, 2017
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20160130587
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: December 22, 2015
    Publication date: May 12, 2016
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9222092
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 29, 2015
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9078855
    Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: July 14, 2015
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Anke Klippel-Giese, Jörg Kaufmann
  • Patent number: 8933215
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: January 13, 2015
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20130065928
    Abstract: Disclosed is the discovery that the mTORC2 complex plays a role in the regulation of PKN3 phosphorylation at the turn motif threonine; and the use of the phosphorylation status of the turn motif threonine of PKN3 as a biomarker. In some embodiments, the phosphorylation status of the turn motif threonine of PKN3 is determined using an antibody that specifically binds to the turn motif threonine of a PKN3 protein, such as an anti-phosphoT860 antibody. In some embodiments, the invention relates to methods for screening compounds that have cancer therapeutic potential, methods for diagnosing cancer, methods for determining the prognosis of a patient suffering from cancer, methods for stratifying patients in a clinical trial, methods for treating a patient suffering from cancer, and methods for determining the effectiveness of a particular treatment regimen.
    Type: Application
    Filed: April 2, 2011
    Publication date: March 14, 2013
    Applicant: WYETH LLC
    Inventors: Anke Klippel-Giese, Keziban Unsal-Kacmaz
  • Patent number: 8324370
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: December 4, 2012
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20120100561
    Abstract: Disclosed are compositions comprising and methods of using a novel macromolecular assembly comprising PKN3, PDK1 and RhoC (PPRC complex). The PPRC complex was shown to have kinase activity and was found in cells of high malignancy potential, such as particularly aggressive cancers. In some aspects, the invention provides methods for screening compounds that have cancer therapeutic potential, methods for diagnosing aggressive cancer, methods for determining the prognosis of a patient suffering from cancer, methods for stratifying patients in a clinical trial or determining the effectiveness of a particular treatment regimen, polypeptides that modulate the formation of the PPRC complex, and kits comprising one or more components of the PPRC complex.
    Type: Application
    Filed: March 12, 2010
    Publication date: April 26, 2012
    Inventors: Anke Klippel-Giese, Keziban Unsal-Kacmaz
  • Publication number: 20110118456
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 19, 2011
    Applicant: SILENCE THERAPEUTICS AG
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese